首页> 外文期刊>Leukemia >Thalidomide as anti-inflammatory therapy for multiple myeloma

【24h】

Thalidomide as anti-inflammatory therapy for multiple myeloma

机译：沙利度胺作为多发性骨髓瘤的抗炎疗法

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia》 |2003年第11期|共2页
作者
P Mehta; M Hussein;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-18 12:14:28

相似文献

外文文献
中文文献
专利

1. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). [J] . Eom HS, Kim YK, Chung JS, Annals of hematology . 2010,第5期

机译：硼替佐米，沙利度胺，地塞米松诱导治疗，美法仑，泼尼松龙，沙利度胺巩固治疗作为非移植候选多发性骨髓瘤患者的第一线治疗方法：韩国多发性骨髓瘤工作组（KMMWP）的结果。
2. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) [J] . Hyeon-Seok Eom, Yeo-Kyeoung Kim, Joo-Seop Chung, Annals of Hematology . 2010,第5期

机译：硼替佐米，沙利度胺，地塞米松诱导治疗，美法仑，泼尼松龙，沙利度胺巩固治疗作为非移植候选多发性骨髓瘤患者的第一线治疗方法：韩国多发性骨髓瘤工作组（KMMWP）的结果
3. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J] . Micheie Cava, Paola Tacchetti, Francesca Patriarca The Lancet . 2010,第9758期

机译：与沙利度胺加上地塞米松的Bortezomib与沙利度胺加上地塞米松作为诱导治疗，并在新诊断出的多发性骨髓瘤中双重自体茎细胞移植：随机相3研究
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A study of microRNAs associated with multiple myeloma pathogenesis and microRNAs/TP53 feedback circuit in human cancers, multiple myeloma and glioblastoma multiforme. [D] . Suh, Sung-Suk. 2012

机译：在人类癌症，多发性骨髓瘤和多形性胶质母细胞瘤中与多发性骨髓瘤发病机制相关的microRNA和microRNA / TP53反馈回路的研究。
6. Efficacy and toxicity of the combination chemotherapy of thalidomide alkylating agent and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study [O] . Jihyun Kwon, Chang‐Ki Min, Kihyun Kim, 2017

机译：沙利度胺烷化剂和类固醇联合化疗对复发/难治性骨髓瘤患者的疗效和毒性：韩国多发性骨髓瘤工作组（KMMWP）回顾性研究的报告
7. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma [O] . Cavo Michele, Pantani Lucia, Petrucci Maria Teresa, 2012

机译：在新诊断的多发性骨髓瘤患者自体造血干细胞移植后，硼替佐米-沙利度胺-地塞米松在巩固治疗方面优于沙利度胺-地塞米松

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号